Commentary Open Access
Volume 6 | Issue 1 | DOI: https://doi.org/10.46439/biomedres.6.058
Clinical insights and research needs in atezolizumab induced neurotoxicity
Mahjoubi Yasmine Salem1,2,*
- 1National Center Chalbi Belkahia of Pharmacovigilance, Tunis, Tunisia
- 2University of Tunis El Manar, Faculty of Medicine, Research Unit: UR17ES12, Tunis, Tunisia
Corresponding Author
Mahjoubi Yasmine Salem, drchittoria@yahoo.com
Received Date: November 04, 2024
Accepted Date: December 09, 2024
Salem MY. Clinical insights and research needs in atezolizumab induced neurotoxicity. J Biomed Res. 2025;6(1):20-25.
Copyright: © 2025 Salem MY. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
DNA hyper methylation editing of T cell receptor signaling and the fellow molecules: a promise strategy of predicting acquired immune checkpoint inhibitors (ICIs) resistance
The promising results of immune checkpoint inhibitors (ICIs) in tumors have changed the current treatment modality for cancer. ICIs response prediction is urgently needed for the personalized therapy approach. In the recent issue of the Journal of Oncology, Zixin Hu et al. proposed that DNA methylation alternations contribute to tumor microenvironment (TME) reshapement to predict the ICIs response. Notwithstanding the global DNA methylation loss, the repression of T cell receptor signaling and the fellow costimulators by DNA hypermethylation contributed to the cold TME and ICIs resistance.
Immune checkpoint inhibitor therapy-associated myocarditis – Toward identification of an immune signature that can improve diagnosis
Immune checkpoint inhibitors (ICI) have emerged as promising treatment options for many cancers. ICIs exert their therapeutic effects by targeting immune inhibitory molecules on T-cells in adaptive immunity, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1). ICIs, however, can result in a wide variety of immune-related adverse events (iRAE), including myocarditis, a rare and potentially deadly complication that necessitates early diagnosis.
Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease
The advent of immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1/PD-L1 pathways has revolutionized cancer treatment with significantly improved outcomes across a spectrum of cancers [1,2]. Although ICI therapy offers significant clinical benefits, these treatments can also lead to various immune-related adverse events (irAEs) that may negatively impact patient outcomes. Although the precise mechanism of irAE is not fully understood, they demonstrate many clinical features similar to autoimmune diseases. IRAEs are thought to result from bystander effects of activated T-cells, cross-reactivity between tumor and host tissues, and the role of the gut microbiome in immune activation [3].